Stéphane Terry
Université Paris-Sud
Research areas: Medicine · Oncology · Prostate Cancer Treatment and Research · Prostate Cancer Diagnosis and Treatment · Cancer Immunotherapy and Biomarkers
0000-0003-3089-7886
About
Scientist and consultant with a background in oncology and immunology, working in basic and translational research. Stephane Terry hold a PhD from the University of Paris-Sud (Paris-Saclay), with early research focused on tumor progression, therapy resistance, and biomarker discovery through close collaboration with clinical and research teams in France and the U.S.
His interests have progressively evolved toward tumor immunology, particularly mechanisms of immune evasion involving NK and T cells, and advancing innovative therapeutic strategies in oncology and beyond, more recently exploring how immune responses influence the efficacy of gene therapy.
Employment
Employment history is unavailable.
Education
- 2004 - 2008
Projects & Funding
Projects & funding information is unavailable.
Publications (76)
- CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity. Save
- Blood MMP-7 and TNF-α levels as potential prognostic biomarkers for adult pulmonary Langerhans cell histiocytosis. Save
- Targeting Aggressive Prostate Carcinoma Cells with Mesothelin-CAR-T Cells Save
- Activity in Group-Housed Home Cages of Mice as a Novel Preclinical Biomarker in Oncology Studies Save
- Designing Organoid Models to Monitor Cancer Progression, Plasticity and Resistance: The Right Set Up for the Right Question Save
- Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. Save
- Cancer stem-like cells evade CD8+CD103+ tumor-resident memory T (TRM) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model Save
- The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes? Save
- Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade Save
- The Most Common VHL Point Mutation R167Q in Hereditary VHL Disease Interferes with Cell Plasticity Regulation Save
- Multifaceted Role of the Transforming Growth Factor β on Effector T Cells and the Implication for CAR-T Cell Therapy Save
- An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment Save
- Waterpipe smoke condensate influences epithelial to mesenchymal transition and interferes with the cytotoxic immune response in non-small cell lung cancer cell lines Save
- Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity? Save
- Selection of tumor‑resistant variants following sustained natural killer cell‑mediated immune stress Save
- Hypoxia-driven intratumor heterogeneity and immune evasion. Save
- AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Save
- Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. Save
- Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade Save
- AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Save